Method for isolating BDCA-4+ dendritic cells
View Patent ↗The application describes, inter alia, a method for isolating or enriching for dendritic cells from a mixture of human cells involving contacting cells in the mixture with an antibody that binds BDCA-4, or antigen-binding fragment thereof, under conditions in which the antibody or antigen-binding fragment binds BDCA-4+ dendritic cells, and separating dendritic cells bound by the antibody or antigen-binding fragment from other cells in the mixture.
1. A method for isolating or enriching for dendritic cells from a mixture of human cells:
a) obtaining a mixture of human cells;
b) contacting cells in the mixture with an antibody that binds BDCA-4, or antigen-binding fragment thereof, under conditions in which the antibody or antigen-binding fragment labels BDCA-4+ dendritic cells; and
c) separating dendritic cells bound by the antibody or antigen-binding fragment from other cells in the mixture:
wherein the mixture of human cells is obtained from bone marrow, peripheral blood, cell culture, umbilical cord blood, tonsil, lymph node, nasal membrane, spleen, skin, airway epithelia, lung, liver, gut, thymus,or Peyers patches.
2. The method of claim 1 wherein the dendritic cells are separated by immunomagnetic cell sorting.
3. The method of claim 1 wherein the dendritic cells are separated by flow cytometry.
4. The method of claim 1 , wherein the mixture of human cells is obtained from bone marrow, from peripheral blood, or from cell culture.
5. The method of claim 1 wherein the mixture of human cells is obtained by leukopheresis of peripheral blood.
6. The method of claim 1 wherein the mixture of human cells is from a source selected from umbilical cord blood, tonsil, lymph node, nasal membrane, spleen, skin, airway epithelia, lung, liver, gut, spleen, thymus, and Peyers patches.
7. The method of claim 1 , further comprising treating the cells with an agent that modulates dendritic cell cytokine production.
8. The method of claim 4 , wherein the mixture of human cells is obtained from peripheral blood.
9. A method for isolating or enriching for human dendritic cells:
a) obtaining human cells from a one or more human hematopoietic tissues, one or more human non-hematopoietic tissues, or both;
b) contacting cells with an antibody that binds BDCA-4, or antigen-binding fragment thereof, under conditions in which the antibody or antigen-binding fragment labels BDCA-4+ dendritic cells; and
c) separating dendritic cells bound by the antibody or antigen-binding fragment thereof from cells that are not bound by the antibody or antigen-binding site.
10. The method of claim 9 wherein the dendritic cells are separated by immunomagnetic cell sorting.
11. The method of claim 9 wherein the dendritic cells are separated by flow cytometry.
12. The method of claim 9 , wherein the human cells are obtained from bone marrow or from peripheral blood.
13. The method of claim 9 wherein the human cells are obtained by leukopheresis of peripheral blood.
14. The method of claim 9 wherein the human cells are from a source selected from umbilical cord blood, tonsil, lymph node, nasal membrane, skin, airway epithelia, lung, liver, gut, spleen, thymus, and Peyers patches.
15. The method of claim 9 , further comprising treating the dendritic cells with an agent that modulates dendritic cell cytokine production.
16. The method of claim 15 , wherein the human cells are obtained from peripheral blood.
17. A method for isolating or enriching for human dendritic cells:
a) obtaining cultured human cells comprising dendritic cells;
b) contacting the cells with an antibody that binds BDCA-4, or antigen-binding fragment thereof, under conditions in which the antibody or antigen-binding fragment labels BDCA-4+ dendritic cells; and
c) separating dendritic cells bound by the antibody or antigen-binding fragment thereof from cells that are not bound by the antibody or antigen-binding fragment thereof.